These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 19822515

  • 1. Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma?
    Shahrokni A, Rajebi MR, Saif MW.
    Clin Colorectal Cancer; 2009 Oct; 8(4):231-4. PubMed ID: 19822515
    [Abstract] [Full Text] [Related]

  • 2. Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene.
    Shahrokni A, Rajebi MR, Harold L, Saif MW.
    JOP; 2009 Mar 09; 10(2):215-20. PubMed ID: 19287123
    [Abstract] [Full Text] [Related]

  • 3. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
    Rosmarin D, Palles C, Pagnamenta A, Kaur K, Pita G, Martin M, Domingo E, Jones A, Howarth K, Freeman-Mills L, Johnstone E, Wang H, Love S, Scudder C, Julier P, Fernández-Rozadilla C, Ruiz-Ponte C, Carracedo A, Castellvi-Bel S, Castells A, Gonzalez-Neira A, Taylor J, Kerr R, Kerr D, Tomlinson I.
    Gut; 2015 Jan 09; 64(1):111-20. PubMed ID: 24647007
    [Abstract] [Full Text] [Related]

  • 4. Capecitabine-induced cerebellar toxicity and TYMS pharmacogenetics.
    Saif MW.
    Anticancer Drugs; 2019 Apr 09; 30(4):431-434. PubMed ID: 30875351
    [Abstract] [Full Text] [Related]

  • 5. Capecitabine: a review.
    Walko CM, Lindley C.
    Clin Ther; 2005 Jan 09; 27(1):23-44. PubMed ID: 15763604
    [Abstract] [Full Text] [Related]

  • 6. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
    Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, Sargent D, Green E, McLeod H, Zanger UM, Schwab M, Braun M, Seymour M, Thompson L, Lacas B, Boige V, Ribelles N, Afzal S, Enghusen H, Jensen SA, Etienne-Grimaldi MC, Milano G, Wadelius M, Glimelius B, Garmo H, Gusella M, Lecomte T, Laurent-Puig P, Martinez-Balibrea E, Sharma R, Garcia-Foncillas J, Kleibl Z, Morel A, Pignon JP, Midgley R, Kerr D, Tomlinson I.
    J Clin Oncol; 2014 Apr 01; 32(10):1031-9. PubMed ID: 24590654
    [Abstract] [Full Text] [Related]

  • 7. A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.
    Lubner SJ, Loconte NK, Holen KD, Schelman W, Thomas JP, Jumonville A, Eickhoff JC, Seo S, Mulkerin DL.
    Clin Colorectal Cancer; 2010 Jul 01; 9(3):157-61. PubMed ID: 20643620
    [Abstract] [Full Text] [Related]

  • 8. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.
    Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, Allan JM, Parmar MK, Quirke P, Seymour MT.
    J Clin Oncol; 2009 Nov 20; 27(33):5519-28. PubMed ID: 19858398
    [Abstract] [Full Text] [Related]

  • 9. Current status of capecitabine in the treatment of colorectal cancer.
    Rothenberg ML.
    Oncology (Williston Park); 2002 Dec 20; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
    [Abstract] [Full Text] [Related]

  • 10. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
    Caronia D, Martin M, Sastre J, de la Torre J, García-Sáenz JA, Alonso MR, Moreno LT, Pita G, Díaz-Rubio E, Benítez J, González-Neira A.
    Clin Cancer Res; 2011 Apr 01; 17(7):2006-13. PubMed ID: 21325291
    [Abstract] [Full Text] [Related]

  • 11. Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity?
    Saif MW, Sandoval A.
    Cutan Ocul Toxicol; 2008 Apr 01; 27(4):311-5. PubMed ID: 19037763
    [Abstract] [Full Text] [Related]

  • 12. Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.
    Jordan K, Kellner O, Kegel T, Schmoll HJ, Grothey A.
    Clin Colorectal Cancer; 2004 May 01; 4(1):46-50. PubMed ID: 15207020
    [Abstract] [Full Text] [Related]

  • 13. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R.
    J Clin Oncol; 2001 Apr 15; 19(8):2282-92. PubMed ID: 11304782
    [Abstract] [Full Text] [Related]

  • 14. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T, Ferraz JM, Zinzindohoué F, Loriot MA, Tregouet DA, Landi B, Berger A, Cugnenc PH, Jian R, Beaune P, Laurent-Puig P.
    Clin Cancer Res; 2004 Sep 01; 10(17):5880-8. PubMed ID: 15355920
    [Abstract] [Full Text] [Related]

  • 15. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD.
    Saif MW.
    Cancer Genomics Proteomics; 2013 Sep 01; 10(2):89-92. PubMed ID: 23603345
    [Abstract] [Full Text] [Related]

  • 16. Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.
    Dong SQ, Wang TM, Zhang JB, He YQ, Xue WQ, Wu ZY, Yang DW, Cao LJ, Huang JW, Li XZ, Zhang PF, Zheng XH, Jia WH.
    Cancer Res Treat; 2021 Jul 01; 53(3):724-732. PubMed ID: 33285053
    [Abstract] [Full Text] [Related]

  • 17. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
    Rini BI, Weinberg V, Small EJ.
    Cancer; 2005 Feb 01; 103(3):553-8. PubMed ID: 15612026
    [Abstract] [Full Text] [Related]

  • 18. Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.
    Weekes CD, Nallapareddy S, Rudek MA, Norris-Kirby A, Laheru D, Jimeno A, Donehower RC, Murphy KM, Hidalgo M, Baker SD, Messersmith WA.
    Invest New Drugs; 2011 Oct 01; 29(5):1057-65. PubMed ID: 20306339
    [Abstract] [Full Text] [Related]

  • 19. Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?
    Do JE, Kim YC.
    Clin Exp Dermatol; 2007 Sep 01; 32(5):519-21. PubMed ID: 17509060
    [Abstract] [Full Text] [Related]

  • 20. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
    Uchida K, Danenberg PV, Danenberg KD, Grem JL.
    BMC Cancer; 2008 Dec 23; 8():386. PubMed ID: 19105824
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.